| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 安图生物始终将技术创新放在战略首位，高度重视研发投入，连续多年，公司研发投入占营业收入的比例均超过13%。2024年研发投入7.32亿，占营业收入的16.37%。 安图生物拥1800余人的研发团队，是业内研发人员最多的企业之一。 安图生物已建立以郑州为中心，北京、上海、苏州、深圳、北美为分支机构的研发体系，充分利用当地的人才和技术优势，组建高素质研发团队，进军体外诊断领域前沿技术和产品的开发。 创建了针对数万个抗原表位的诊断抗体库，免疫诊断试剂产品的抗原抗体自给率高，保证了供应的稳定性和安全性。 建设中的安图生物体外诊断产业园，建设用地面积251亩，全面建成后，将成为中国最大的体外诊断产业基地之一。 安图生物引入自动化生产线，提高产品自动化和流水作业程度;提升精细化管理水平，提高生产效率;通过研发改进、工艺提升，不断优化，提高产品的稳定性。 安图生物已通过GMP、ISO9001和IS013485等认证考核;安图生物参考实验室通过CNASIS017025认可;严格质量管理考核，持续促进质量提升。 | ||||||||||||||||||||||||
| Main Business | 体外诊断试剂和仪器的研发、制造、整合及服务。 | ||||||||||||||||||||||||
| Legal Representative | 杨增利 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 房瑞宽 | ||||||||||||||||||||||||
| Solicitors | 上海市锦天城律师事务所 | ||||||||||||||||||||||||
| Auditors | 中勤万信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0371-86506868 | ||||||||||||||||||||||||
| Fax No | 0371-86506767 | ||||||||||||||||||||||||
| Website | www.autobio.com.cn | ||||||||||||||||||||||||
| autobio@autobio.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 01/09/2016 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.870 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 1.310 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 15.621 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 19.183B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |